Goldshtein I, Nevo D, Steinberg DM, et al. - In this retrospective cohort analysis of pregnant women, BNT162b2 mRNA vaccination was linked with a significantly decreased risk of SARS-CoV-2 infection when compared with no vaccination.

• The cohort included 7,530 vaccinated and 7,530 matched unvaccinated women, with a mean age of 31.1 years (SD, 4.9 years) and 46% and 33% in the second and third trimesters, respectively.

• The primary outcome had a median follow-up of 37 days (interquartile range, 21-54 days; range, 0-70).

• The vaccinated group had 118 SARS-CoV-2 infections, while the unvaccinated group had 202.

• In the vaccinated group, 88 of 105 (83.8%) of infected women were symptomatic, compared to 149 of 179 (83.2%) in the unvaccinated group.

• There were 10 infections in the vaccinated group and 46 in the unvaccinated group during 28 to 70 days of follow-up.

• The risks of infection in the vaccinated and unvaccinated groups were 0.33% and 1.64%, respectively, representing an absolute difference of 1.31% and an adjusted hazard ratio of 0.22.

• Sixty-eight patients reported vaccine-related adverse events, none of which were severe.

• Headache, general weakness, nonspecified pain, and stomachache were the most frequently reported symptoms.